Figure S4. Zoledronic acid arrests the cell cycle of cervical cancer cells. The histograms show the proportions of cell cycle distribution in G1, S, and G2/M phase of HeLa, SiHa, and CaSki cells through flow cytometry analysis. Control vs. 10, 20, and 30 μM of Zoledronic acid: * P < 0.05, ** P < 0.01. Results are shown as mean values ± SD of independent experiments performed in triplicate. (TIF 380 kb
Peripheral blood counts represented as average fold change in nude (a) and C57BL/6 (b) mice 3 and 5 ...
WOS: 000432895500002PubMed ID: 29300112Unlike low tumorigenic bulk tumor cells (non-CSCs), cancer st...
Figure S1. Reduced expression of Zc3h8 in a second cell line and using a second targeting shRNA lead...
Figure S3. Zoledronic acid induces apoptosis of cervical cancer cells. The histograms show the propo...
Figure S2. Zoledronic acid affects the cervical cancer cells with stemness phenotype. Approximately ...
Figure S5. Zoledronic acid acts through the MPAK- and PI3K/Akt-pathways related proteins of cervical...
Figure S1. Identification of the stemness phenotypic characteristics of SiHa and CaSki cells derived...
Flow cytometry cell-surface markers used to quantify indicated hematopoietic stem and progenitor cel...
a Growth kinetics of tumors after injecting host nude mice subcutaneously with admixtures of MDA-MB-...
Figure S3. The effect of C.M. from breast cancer cells on Tregs migration. Tregs (5 × 10 4) were pla...
Figure S2. The effects of C.M. from MCF-7 cells on Tregs proliferation. Total counts of viable Tregs...
Abstract Background Zoledronic acid is the most potent osteoclast inhibitor and is widely used for a...
Figure S1. C.M. of MDA-MB-231 cells enhanced Tregs proliferation. Total counts of viable Tregs stimu...
Additional file 1: Figure S1. Cell proliferation using alamarblue® assay (a) and Vybrant MTT® assay ...
Figure S1. Zoledronate (ZOL) at the ÎźM level presents a dose-dependently inhibitory effect on cellu...
Peripheral blood counts represented as average fold change in nude (a) and C57BL/6 (b) mice 3 and 5 ...
WOS: 000432895500002PubMed ID: 29300112Unlike low tumorigenic bulk tumor cells (non-CSCs), cancer st...
Figure S1. Reduced expression of Zc3h8 in a second cell line and using a second targeting shRNA lead...
Figure S3. Zoledronic acid induces apoptosis of cervical cancer cells. The histograms show the propo...
Figure S2. Zoledronic acid affects the cervical cancer cells with stemness phenotype. Approximately ...
Figure S5. Zoledronic acid acts through the MPAK- and PI3K/Akt-pathways related proteins of cervical...
Figure S1. Identification of the stemness phenotypic characteristics of SiHa and CaSki cells derived...
Flow cytometry cell-surface markers used to quantify indicated hematopoietic stem and progenitor cel...
a Growth kinetics of tumors after injecting host nude mice subcutaneously with admixtures of MDA-MB-...
Figure S3. The effect of C.M. from breast cancer cells on Tregs migration. Tregs (5 × 10 4) were pla...
Figure S2. The effects of C.M. from MCF-7 cells on Tregs proliferation. Total counts of viable Tregs...
Abstract Background Zoledronic acid is the most potent osteoclast inhibitor and is widely used for a...
Figure S1. C.M. of MDA-MB-231 cells enhanced Tregs proliferation. Total counts of viable Tregs stimu...
Additional file 1: Figure S1. Cell proliferation using alamarblue® assay (a) and Vybrant MTT® assay ...
Figure S1. Zoledronate (ZOL) at the ÎźM level presents a dose-dependently inhibitory effect on cellu...
Peripheral blood counts represented as average fold change in nude (a) and C57BL/6 (b) mice 3 and 5 ...
WOS: 000432895500002PubMed ID: 29300112Unlike low tumorigenic bulk tumor cells (non-CSCs), cancer st...
Figure S1. Reduced expression of Zc3h8 in a second cell line and using a second targeting shRNA lead...